Alphabet Inc, the parent company of Google, is introducing a new venture by the name of Isomorphic Labs that will put artificial intelligence to good use for the discovery of new medicines.
With an AI-first approach, Isomorphic Labs is a new Alphabet company that promises to "reimagine the entire drug discovery process." In a highly collaborative environment, the company will leverage biology, medicinal chemistry, biophysics, engineering and more to approach drug discovery like never before.
This start-up will fall under the company’s London research laboratory, DeepMind. Already, algorithms from DeepMind have been helpful for predicting the shapes of proteins (with atomic-level accuracy) and this technology has the potential to be an asset for studying and inventing the future of medicine.
Key Themes Behind This Trend
- AI-first Medicine Discovery
- Isomorphic Labs will apply an AI-first approach to discover new medicines and streamline drug discovery.
- Collaborative Approach to Drug Discovery
- Isomorphic Labs' highly collaborative approach to drug discovery brings together multiple disciplines, including biology, medicinal chemistry, biophysics, and engineering.
- Protein Prediction Algorithm Application
- Isomorphic Labs aims to utilize the protein prediction algorithm developed by DeepMind to study and invent new medicine.
Where This Applies
- Pharmaceutical Industry
- The pharmaceutical industry has a disruption opportunity in adopting an AI-first approach to drug discovery, and leveraging collaboration between different scientific disciplines.
- Artificial Intelligence Industry
- The AI industry has an opportunity to innovate by creating new tools and technologies tailored specifically for drug discovery and protein prediction.
- Biotech Industry
- The biotech industry has a disruptive opportunity to integrate AI and machine learning into drug discovery and the development of new medicines.
